Zepbound Side Effects: Nausea, Hair Loss & Timeline (2026)

01

The most common Zepbound side effects

In placebo-controlled weight-management trials (SURMOUNT-1 and SURMOUNT-2), gastrointestinal reactions were the most frequently reported Zepbound side effects, and they were clearly dose-related. According to the FDA-approved Zepbound label, reactions occurring in ≥5% of patients were nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia (indigestion), injection-site reactions, fatigue, hypersensitivity reactions, eructation (belching), hair loss, and gastroesophageal reflux disease.

The label reports the following approximate incidence for Zepbound (pooled across the 5, 10, and 15 mg maintenance doses):

(Source: FDA Zepbound prescribing information, SURMOUNT-1/2 pooled. Each of these was several-fold higher than placebo — for example, nausea and diarrhea were about 8% on placebo. Individual experience varies.)

Crucially, most GI symptoms were mild to moderate, occurred during dose escalation, and only a minority led to stopping the drug.

Discontinuation for gastrointestinal reactions was about 3.3% at 10 mg and 4.3% at 15 mg, versus 0.5% on placebo — meaning most people who felt sick did not stop treatment.

Zepbound nausea

Nausea is the single most common Zepbound side effect — reported by roughly 25–29% of adults in trials versus about 8% on placebo.

It typically peaks in the first days after starting or after a dose increase, then settles as your body adjusts to tirzepatide's roughly 5-day half-life.

Practical strategies widely recommended by clinics such as Cleveland Clinic and Mayo Clinic: eat smaller, more frequent meals, eat slowly and stop at the first feeling of fullness, favor bland, low-fat foods, and sip fluids between meals rather than with them.

Greasy, fried, and very sweet foods tend to make nausea worse.

If nausea is disruptive, some clinicians prescribe a short course of an anti-nausea medicine around dose increases. (Deep-dive: how to manage GLP-1 nausea.)

Injection-site reactions

Because Zepbound is a weekly subcutaneous injection, injection-site reactions — redness, itching, or a small firm bump — are among the labeled adverse reactions (reported by roughly 6–9% of patients, more than placebo).

They are usually mild and short-lived. Rotating the injection site each week (abdomen, thigh, upper arm) and letting the pen reach room temperature before injecting can reduce sting and local reactions.

Persistent, spreading, or painful lumps should be shown to your clinician.

Vomiting, diarrhea, and constipation

Vomiting (8–13%) and diarrhea (19–23%) are common on Zepbound and can cause a real problem: dehydration. Because tirzepatide also blunts thirst and appetite, it is easy to under-drink.

Persistent vomiting or diarrhea that keeps you from holding down fluids is a reason to call your clinician — partly because severe dehydration can, in rare cases, trigger acute kidney injury (see serious effects below).

Constipation (11–17%) stems from the same slowed gut motility; more fiber, fluids, and movement usually help, but severe cramping with bloating and vomiting can signal a blockage.

Zepbound hair loss

Like the Wegovy label, the Zepbound label lists hair loss (alopecia) — reported by about 5% of adults, more often than placebo.

Importantly, dermatologists generally attribute this shedding not to a direct toxic effect of tirzepatide but to telogen effluvium: a temporary, reversible form of hair shedding triggered by the rapid weight loss and nutritional shift that come with effective treatment.

Because tirzepatide drives some of the largest average weight loss of any current obesity drug, hair thinning is reported.

Shedding usually appears about two to four months after the trigger and typically recovers on its own as weight stabilizes.

Eating enough protein and a nutrient-varied diet — easy to under-do when appetite drops — helps protect hair. Persistent or patchy loss warrants a check for iron or other deficiencies.

Other common effects

People also report belching, heartburn/reflux, gas, bloating, fatigue, dizziness, and hypersensitivity (allergic) reactions. These are usually mild.

02

How long do Zepbound side effects last?

For most people, the common gastrointestinal side effects are temporary. Nausea and related symptoms most often ease within a few weeks of starting Zepbound or of each dose increase, as the body adjusts — a pattern clinics describe as typical for incretin medicines, though some people feel effects longer.

Because side effects cluster around dose changes, a slow, gradual dose escalation is the single most effective way to limit them, which is why the manufacturer builds in a multi-week titration schedule that begins at a low, non-maintenance 2.5 mg starter dose.

The Zepbound label's titration is stepwise: 2.5 mg for the first 4 weeks (a starter dose, not a maintenance dose), then increases in 2.5 mg increments at intervals of at least four weeks — 5 mg, 7.5 mg, 10 mg, 12.5 mg — up to a maximum of 15 mg once weekly.

The available maintenance doses are 5, 10, and 15 mg (with 7.5 and 12.5 mg as intermediate steps).

If a side effect is still severe after several weeks, or you are losing weight faster than intended, that is a signal to talk with your prescriber, who may hold or step down your dose.

Do not change your own dose without medical guidance.

03

Dose-dependence: why 2.5 mg to 15 mg matters

Zepbound side effects are strongly dose-dependent. In the trials, both severe GI reactions (5 mg ~1.7%, 10 mg ~2.5%, 15 mg ~3.1% vs 1.0% placebo) and GI-related discontinuations rose with dose.

This is why the prescribing information uses a stepwise titration rather than starting at the full dose, and why the starter 2.5 mg is explicitly not a treatment dose.

The most reliable predictor of how you will tolerate Zepbound is how quickly the dose is increased, not any personal "toughness." If a step is hard, prescribers can hold you at the current dose longer before stepping up.

04

Serious Zepbound side effects and warnings

These are less common but important, and they are why Zepbound is prescription-only and medically supervised.

Pancreatitis

The Zepbound label warns that acute pancreatitis has been observed with GLP-1-based therapies.

In the pooled weight-management trials the adjudicated rate was low and similar to placebo (about 0.2% in each group), but the warning stands because cases — including serious ones — have occurred.

The classic sign is severe, persistent abdominal pain, often in the upper abdomen and sometimes radiating to the back, with or without vomiting.

Manufacturer guidance is explicit: stop the medicine and seek care promptly; if pancreatitis is confirmed, do not restart.

Gallbladder problems and gallstones

Treatment with Zepbound is associated with gallbladder disease. In the pooled trials, cholelithiasis (gallstones) occurred in about 1.1% of Zepbound-treated patients (vs 1.0% placebo), cholecystitis in 0.7% (vs 0.2%), and some patients required cholecystectomy (gallbladder removal).

Acute gallbladder events were linked to the degree of weight loss.

Warning signs include pain in the upper-right abdomen, fever, yellowing of the skin or eyes (jaundice), and clay-colored stools.

Delayed gastric emptying, severe GI reactions, and aspiration risk

Zepbound slows stomach emptying by design, but in some people this becomes problematic.

The label warns of severe gastrointestinal reactions, including ileus (intestinal blockage) in postmarketing reports.

A related concern is a rare risk of pulmonary aspiration during general anesthesia or deep sedation, because food may remain in the stomach — so tell your care team you take Zepbound before any surgery or procedure with sedation.

Boxed warning: thyroid C-cell tumors

Tirzepatide carries the FDA's strongest boxed warning for thyroid C-cell tumors, based on findings in rodents; whether this applies to humans is not known. Zepbound is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Report a lump in the neck, trouble swallowing, shortness of breath, or persistent hoarseness.

Kidney injury, hypoglycemia, heart rate

There have been reports of acute kidney injury — some needing dialysis — mostly in people who became dehydrated from nausea, vomiting, or diarrhea.

On its own Zepbound carries a low hypoglycemia risk, but the risk rises with insulin or a sulfonylurea in people who also have type 2 diabetes.

The label also flags a modest increase in heart rate and, for people with type 2 diabetes, diabetic retinopathy monitoring.

Hypersensitivity and mood

Serious hypersensitivity reactions (including anaphylaxis and angioedema) have been reported — stop the drug and get emergency care for swelling of the face/lips/throat or trouble breathing.

As a weight-management product, the label also instructs clinicians to monitor for depression, suicidal thoughts, or unusual mood changes. For added context: after formal 2024 reviews, both the U.S. FDA and the European Medicines Agency concluded the available evidence does not support a causal link between GLP-1-based medicines and suicidal or self-harm thoughts.

Still, report any new or worsening mood changes to your clinician.

05

When to seek care: Zepbound red-flag table

When in doubt, call your clinician or emergency services — this table is a guide, not a substitute for professional judgment.

06

Zepbound vs Mounjaro side effects: same molecule

Zepbound and Mounjaro are both tirzepatide, so they share the same side-effect profile. The differences are in approved use and branding, not the drug itself:

Because they are the same molecule at the same dose range, the side effects are the same; the label differs only in indication.

Compared with semaglutide (Wegovy), tirzepatide adds GIP action and, in trials, tends to produce greater average weight loss — which can also mean more GI complaints at higher doses.

For the semaglutide profile, see our Wegovy side effects guide.

07

Practical ways to reduce Zepbound side effects

1. Go slow. Follow the titration schedule; never rush to a higher dose on your own.
2. Eat smaller, more frequent, lower-fat meals and stop at the first sign of fullness.
3. Hydrate — sip water through the day, especially with any vomiting or diarrhea.
4. Limit greasy, fried, very sweet, and heavily processed foods, which worsen nausea.
5. Add fiber and move your body to counter constipation.
6. Rotate your injection site each week and let the pen warm up to reduce local reactions.
7. Prioritize protein and gradual weight loss to protect muscle and reduce hair shedding.
8. Track your symptoms, doses, and meals — and report red-flag symptoms immediately rather than "waiting it out."

Because Zepbound side effects cluster around specific days and doses, a simple daily log of what you feel, when you dosed, and what you ate makes conversations with your clinician far more useful.

This is exactly what the Havit app is built to make effortless — log your dose, injection site, meals, and how you feel, and see your own patterns over time. (It's a tracking companion, not a medical device — always defer to your clinician.)

08

Why HAVIT — Medication + Behavior Change, in One App

GLP-1 medications can meaningfully reduce weight — but the number on the scale is only part of the story.

Roughly 20–40% of the weight lost on GLP-1 therapy can come from lean (muscle) tissue rather than fat (Neeland et al., Diabetes, Obesity and Metabolism, 2024), and results tend to fade once the medication stops unless new habits take their place.

That's why leading guidance treats medication as one part of care, not the whole: the U.S. Preventive Services Task Force recommends that adults with obesity be offered intensive, multicomponent behavioral interventions (USPSTF, Grade B).

HAVIT is built for exactly this moment — one app that unites medication tracking, body composition, nutrition and protein, daily habit-building, and an AI coach that adapts to you.

Across our own 1,090 GLP-1 users, the most consistent trackers built the strongest habits (see the GLP-1 habit report).

Manage the medicine and the muscle — together. Start with HAVIT →

The most common Zepbound side effects

Related articles